Safe & Gentle Wound Care for Faster Recovery

ComBatic™ Hydrogel forms a protective, hydrated barrier over the wound surface that helps soften and loosen wound debris for easier, pain-free dressing changes. The formulation helps maintain a clean and balanced wound environment, supporting faster natural healing and reducing the risk of contamination and odor.

Unmet need

Chronic wounds with biofilms require novel, more effective, life-saving treatments

+90%

Chronic wounds involve Biofilm

30 Seconds

A Leg is Amputated Due to Diabetic Foot Ulcers

50%

Mortality Rate After a Diabetic Foot Ulcer Amputation

Smart Wound Barrier for Faster, Safer Healing

ComBatic™ Hydrogel forms a protective, hydrated barrier over the wound surface that maintains moisture, supports the body’s natural healing process, and shields the wound from external contaminants.

Moist Environment That Promotes Recovery

Its viscous gel structure prevents desiccation, allowing tissue regeneration to occur in an optimal moist environment while reducing dressing-change pain and trauma.

Helps Protect Against Microbial Contamination

Formulated with carefully selected ingredients that help preserve the hydrogel and limit microbial growth within the dressing, supporting a clean and balanced wound environment.

Biocompatible, Gentle, and Non-Toxic

The formulation is made with biocompatible, non-cytotoxic, and novel safe composition designed to be gentle on skin while maintaining excellent safety and low irritation potential.

18,000+

Formulations Screened to find the optimal solution.

Explore Our Pipeline

Wound Care – Medical Device

Science and ongoing R&D supporting ComBatic™ technology

  • A hydrated barrier that protects the wound and maintains moisture to facilitate healing.
  • Control biofilms and improves antimicrobial efficacy
  • Non-toxic with antioxidant properties to promote healing
  • Reduces infection recurrence and potential resistance

Biofilms are structured microbial communities that form on wound surfaces, delaying healing and increasing infection risk. Over 90% of chronic wounds, including diabetic foot ulcers, involve biofilms, leading to prolonged treatment, higher healthcare costs, and increased risk of amputation. Combiotic™ technology has been developed after screening 18,000+ formulations, demonstrating efficacy in biofilm disruption, infection control, and wound recovery acceleration while minimizing toxicity and antimicrobial resistance.

Advancing Antimicrobial Solutions for Critical Infections

Innovative Pipeline

Medical Devices

Discovery

Validation

Biocompatibility

Approval

Commercialization

ComBatic™ Antimicrobial Wound Care

Therapeutics

Discovery

Pre-Clinical

Phase I

Phase II

Phase III

COMB-NEBTM for Respiratory Infection

Therapeutics

Discovery

Pre-Clinical

Phase I

Phase II

Phase III

MHC-200 for Systemic infection

Let’s Connect and Innovate Together

Have questions about our technology, research, or partnerships? We’d love to hear from you!

Contact us